Achieve Life Sciences Advances Cytisinicline for Smoking Cessation at J.P. Morgan Conference

Achieve Life Sciences Advances Smoking Cessation Solutions with Cytisinicline

Achieve Life Sciences, Inc. announces its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, scheduled for January 12-15, 2026. During this event, CEO Rick Stewart and senior management will engage in one-on-one meetings to discuss the company’s late-stage development of cytisinicline, a promising treatment for nicotine dependence. The focus is particularly on the drug’s potential for aiding smoking and vaping cessation, as well as the company’s strategic plans for the upcoming year. This gathering provides an important platform for Achieve Life Sciences to highlight the significance of its work in addressing nicotine addiction, a critical public health issue.

Recently, Achieve Life Sciences received acceptance for its New Drug Application (NDA) for cytisinicline from the U.S. Food and Drug Administration (FDA). The Prescription Drug User Fee Act (PDUFA) date is set for June 20, 2026, marking a significant milestone for the company. This NDA is supported by data from two completed Phase 3 studies and an additional safety study, demonstrating cytisinicline's efficacy in treating nicotine dependence in adults. The company has also successfully conducted a Phase 2 study focused on vaping cessation and engaged in a productive end-of-Phase 2 meeting with the FDA regarding this indication. These developments underscore Achieve’s commitment to providing effective therapeutic options in a landscape where nicotine addiction remains a pressing concern.

The urgency for effective cessation solutions is underscored by the alarming statistics surrounding tobacco and e-cigarette use in the United States. Approximately 29 million adults currently smoke combustible cigarettes, contributing to over eight million deaths globally each year, with nearly 500,000 occurring annually in the U.S. Furthermore, about 17 million adults use e-cigarettes, with a notable increase among youth. In 2024, 1.6 million middle and high school students reported using e-cigarettes. Despite the high prevalence of nicotine dependence, there are currently no FDA-approved treatments specifically targeting e-cigarette cessation, accentuating the need for effective interventions like cytisinicline.

Cytisinicline, a plant-based alkaloid, shows promise by binding to nicotinic acetylcholine receptors, potentially helping individuals combat their nicotine addiction. As Achieve Life Sciences prepares for its upcoming conference and continues to advance its research and development efforts, it stands at the forefront of addressing a critical health challenge. For those interested in learning more or scheduling meetings, Achieve’s Investor Relations team is available to facilitate connections.